RxDoctor Payments Data

Allyson Martin, PA

Physician Assistant · Redding, CANPI 1528272069

Payments from drug & device makers

$2,909in general payments, 2019–2025

Across 141 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$430
  • Johnson & Johnson$359
  • Abbott$313
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$275
  • Boehringer Ingelheim$268
  • AstraZeneca$261
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,909 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$140,168
Medicare patients
853
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$253,842
EntrestoSacubitril/Valsartan86$136,012
JardianceEmpagliflozin74$110,147
MultaqDronedarone Hcl16$23,124
XareltoRivaroxaban19$20,849
Dabigatran EtexilateDabigatran Etexilate Mesylate15$6,509
Metoprolol Succinate179$3,082
Valsartan62$2,278
Losartan Potassium193$1,714
Nifedipine ErNifedipine38$1,347
SotalolSotalol Hcl58$1,104
Potassium Chloride49$1,101
Amiodarone Hcl28$1,092
Amlodipine Besylate154$1,053
Flecainide Acetate20$953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$253,842164 claims
NovartisEntresto$430$136,01286 claims
Boehringer IngelheimJardiance$268$110,14774 claims
Johnson & JohnsonXarelto$359$20,84919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →